
C4 Therapeutics Inc is a biotechnology business based in the US. C4 Therapeutics Inc shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics Inc employs 121 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in C4 Therapeutics Inc
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CCCC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

C4 Therapeutics Inc stock price (NASDAQ: CCCC)
Use our graph to track the performance of CCCC stocks over time.C4 Therapeutics Inc shares at a glance
Latest market close | $8.03 |
---|---|
52-week range | $4.84 - $51.21 |
50-day moving average | $7.25 |
200-day moving average | $25.85 |
Wall St. target price | $29.64 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.99 |
Buy C4 Therapeutics Inc shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy C4 Therapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
C4 Therapeutics Inc price performance over time
Historical closes compared with the close of $8.03 from 2022-07-01
1 week (2022-06-28) | 12.31% |
---|---|
1 month (2022-06-01) | N/A |
3 months (2022-04-05) | -63.50% |
6 months (2022-01-05) | -72.90% |
1 year (2021-07-02) | -79.78% |
---|---|
2 years (2020-07-01) | N/A |
3 years (2019-07-01) | N/A |
5 years (2017-07-01) | N/A |
C4 Therapeutics Inc financials
Revenue TTM | $46 million |
---|---|
Gross profit TTM | $-41,354,000 |
Return on assets TTM | -13.07% |
Return on equity TTM | -30.1% |
Profit margin | -205.47% |
Book value | $7.48 |
Market capitalisation | $367.9 million |
TTM: trailing 12 months
C4 Therapeutics Inc share dividends
We're not expecting C4 Therapeutics Inc to pay a dividend over the next 12 months.
C4 Therapeutics Inc overview
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Frequently asked questions
What percentage of C4 Therapeutics Inc is owned by insiders or institutions?Currently 11.28% of C4 Therapeutics Inc shares are held by insiders and 92.989% by institutions. How many people work for C4 Therapeutics Inc?
Latest data suggests 121 work at C4 Therapeutics Inc. When does the fiscal year end for C4 Therapeutics Inc?
C4 Therapeutics Inc's fiscal year ends in December. Where is C4 Therapeutics Inc based?
C4 Therapeutics Inc's address is: 490 Arsenal Way, Watertown, MA, United States, 02472 What is C4 Therapeutics Inc's ISIN number?
C4 Therapeutics Inc's international securities identification number is: US12529R1077
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert